CNIC

ECS President John Heneghan Named Wash100 Award Winner

Retrieved on: 
Wednesday, February 21, 2024
Security, Government Technology, Defense, White House, Federal Government, State, Local, Other Technology, Contracts, Artificial Intelligence, Networks, Internet, Consulting, Homeland Security, Data Management, Professional Services, Technology, Public Policy, Government, Health, Health Technology, ECS, Intelligence, Digital, Risk, CNIC, IDIQ, ERG, Pathfinder, Machine learning, Science, Veterans' affairs, Environment, STATS, Commander, Navy Installations Command, Medical device

ECS , a leader in advanced technology, science, and engineering solutions and an ASGN (NYSE: ASGN) brand, announced today that President John Heneghan has been recognized as a 2024 Wash100 Award winner by Executive Mosaic, an international leadership organization and media company.

Key Points: 
  • ECS , a leader in advanced technology, science, and engineering solutions and an ASGN (NYSE: ASGN) brand, announced today that President John Heneghan has been recognized as a 2024 Wash100 Award winner by Executive Mosaic, an international leadership organization and media company.
  • This marks the third consecutive year that Heneghan has been recognized on the list.
  • Heneghan assumed the role of ECS president in 2022.
  • “I’m proud to be named to the Wash100 list once again, because it reflects the value of the work we do and the impact our teams make on government missions,” said Heneghan.

AM Best Places Credit Ratings of Consolidated National Insurance Company Under Review With Developing Implications

Retrieved on: 
Wednesday, February 21, 2024
Professional Services, Insurance, Finance, ALL, News, AM Best, Credit rating, CNIC, Credit, Security (finance)

AM Best has placed under review with developing implications the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Rating of “a-” (Excellent) of Consolidated National Insurance Company (CNIC) (Littleton, CO).

Key Points: 
  • AM Best has placed under review with developing implications the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Rating of “a-” (Excellent) of Consolidated National Insurance Company (CNIC) (Littleton, CO).
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings .
  • For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments .
  • AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry.

The World Health Organization Includes the Cardiovascular Polypill Developed by the Spanish National Centre for Cardiovascular Research and Ferrer in its List of Essential Medicines

Retrieved on: 
Wednesday, August 2, 2023
Medical Supplies, Health, Other Health, Pharmaceutical, Cardiology, Biotechnology, Business development, Essential, Myocardial infarction, The New England Journal of Medicine, Atorvastatin, Ferrer, NEJM, Mount Sinai Hospital, Patient, Mortality, WHO, CNIC, Director general, World Health Organization, Essential medicines, Dietary supplement, Medical device, Pharmaceutical industry, Medicine, Ramipril

The cardiovascular polypill developed by the Spanish National Centre for Cardiovascular Research (CNIC) and Ferrer has been included by the World Health Organization (WHO) in its List of Essential Medicines 1.

Key Points: 
  • The cardiovascular polypill developed by the Spanish National Centre for Cardiovascular Research (CNIC) and Ferrer has been included by the World Health Organization (WHO) in its List of Essential Medicines 1.
  • This cardiovascular polypill includes three active ingredients (acetylsalicylic acid, ramipril and atorvastatin) and has been proven to be effective in preventing cardiovascular events after a heart attack, reducing mortality from cardiovascular causes by 33%.
  • This was evidenced by the SECURE 2 study, with results published in August 2022 in the New England Journal of Medicine 3 (NEJM).
  • As stated in the WHO report , “essential medicines are those that satisfy the priority health care needs of a population.

ECS Wins $154M IT Ops US Navy Contract

Retrieved on: 
Tuesday, August 1, 2023
Security, Defense, White House, Federal Government, Other Technology, State, Local, Other Defense, Contracts, Networks, Consulting, Internet, Building Systems, Other Construction & Property, Professional Services, Data Management, Technology, Public Policy, Government, Construction & Property, Law Enforcement, Emergency Services, Military, Science, Navy, CNIC, Communication, Partnership, Public safety network, Improper integral, Commander, Navy Installations Command, N61, Marines, ECS, Engineering, Management, Risk management

ECS, a leader in advanced technology, science, and engineering solutions, has won a contract valued at $154M with the U.S. Navy’s Commander, Navy Installations Command (CNIC) .

Key Points: 
  • ECS, a leader in advanced technology, science, and engineering solutions, has won a contract valued at $154M with the U.S. Navy’s Commander, Navy Installations Command (CNIC) .
  • With one base year and four option years, the contract will continue ECS’ support of the CNIC IT services branch N61, responsible for infrastructure engineering and delivery.
  • ECS and N61 continue to modernize what has historically been known as Public Safety Network (PSNet), which enables Navy CNIC mission-operations systems worldwide.
  • These include systems for first-responder emergency management and communication for the Navy and Marine Corps, and enterprise building and utility control for Navy installations.

First-Ever Carbon Neutral Commodity Futures Index ETF (NYSE: AMPD) Launches from CNIC Funds and Tidal Financial Services

Retrieved on: 
Friday, May 19, 2023
Environment, Finance, Other Energy, Utilities, Banking, Professional Services, Sustainability, Energy, Asset Management, Carbon, National Snow and Ice Data Center, Partnership, CPI, RISK, ALL, ICE, INDEX, Calendar, Electricity, OR, Trust, DATA, EXPRESS, ETF, Transport, Intercontinental Exchange, NYSE, CNIC, Financial adviser, Cryptocurrency, Renewable energy, Index

CNIC Funds, LLC , (CNIC) an investment company that develops commodity-based investment products in partnership with Tidal Financial Services, LLC (Tidal), proudly announces the launch of the exchange-traded fund, CNIC ICE U.S.

Key Points: 
  • CNIC Funds, LLC , (CNIC) an investment company that develops commodity-based investment products in partnership with Tidal Financial Services, LLC (Tidal), proudly announces the launch of the exchange-traded fund, CNIC ICE U.S.
  • Carbon Neutral Power Futures Index ETF (NYSE: AMPD).
  • Carbon Neutral Power Index (ticker: ICECNPIT) that was launched on January 18, 2023, by Intercontinental Exchange, Inc. (ICE).
  • Carbon Neutral Power Index (“Index”) for use by CNIC, LLC in connection with CNIC ICE U.S.

ACIC Pharmaceutical Machinery Inc. joins the CNIC to help Canadian companies bring radiopharmaceutical products “from Molecule to Market”

Retrieved on: 
Tuesday, February 7, 2023
Nuclear medicine, Automation, Machine, PMI, Isotope, Artificial intelligence, CNIC, ACIC, Radiopharmaceutical, Research, Medical imaging

Together, the CNIC and ACIC Machinery will work to encourage future partnerships by bringing industry-leading technology to the Canadian radiopharmaceutical market.

Key Points: 
  • Together, the CNIC and ACIC Machinery will work to encourage future partnerships by bringing industry-leading technology to the Canadian radiopharmaceutical market.
  • As a North American company branching into the Canadian isotope market, ACIC Machinery is looking to provide radiopharmaceutical companies across Canada with manufacturing and technology solutions.
  • With a global network of clients and partners, ACIC Machinery has been a key supplier to the North American pharmaceutical industry.
  • We look forward to facilitating collaboration between ACIC Machinery and other CNIC members in this powerful industry.”
    To learn more about ACIC Pharmaceutical Machinery, visit https://acicmachinery.com/ and follow on LinkedIn.

ICE Launches Carbon-Neutral U.S. Electricity Futures Index

Retrieved on: 
Monday, January 23, 2023
Other Energy, Utilities, Data Analytics, Finance, Alternative Energy, Energy, Professional Services, Fintech, Carbon, Consumer, ICE, CNIC, Electricity, Intercontinental, Iron ore, Renewable energy

Intercontinental Exchange, Inc., a leading global provider of data, technology and market infrastructure, today announced the launch of the first carbon-neutral U.S. electricity futures index.

Key Points: 
  • Intercontinental Exchange, Inc., a leading global provider of data, technology and market infrastructure, today announced the launch of the first carbon-neutral U.S. electricity futures index.
  • Carbon Neutral Power Index provides investors with a benchmark that contains exposure to the critical North American power markets.
  • Carbon Neutral Power Index consists of the prompt twelve months of ICE-listed electricity futures contracts from six major U.S. power pools as well as carbon allowance futures contracts designed to offset the emissions of the generation associated with these electricity futures contracts.
  • “This index will assist us in developing financial instruments that provide investors exposure to exchange-traded electricity futures and carbon offsets, while having the ability to use the ICE U.S.

More Than 350 Latin American Doctors Take Part in the Region's Second Ferrer Summit

Retrieved on: 
Monday, October 24, 2022
Health, Hospitals, Surgery, Neurology, Pharmaceutical, Cardiology, The New England Journal of Medicine, Aspirin, CNIC, Cardiology, Social change, Tree, Translation, Patient, Hospital, Farmer, Gastroenterology, Ramipril, Workforce, Multimedia, Mortality, Lists of diseases, George C. Marshall European Center for Security Studies, Home Away from Homer, Atorvastatin, Learning, Neurology, CEO, Awareness, Ferrer, Wind, Dominican Republic, Summit, NEJM, Environment, Travel, USD, Spanish National Center for Biotechnology, CO2, Medical device, Medicine, Renewable energy, Pharmaceutical industry

With the participation of more than 350 specialist doctors from Latin American countries such as Panama, Guatemala, El Salvador, Nicaragua, Honduras, the Dominican Republic, Colombia, Bolivia, Chile, Paraguay, Peru, Mexico, Costa Rica, and Argentina, the second LatAm Ferrer Summit was held in Panama.

Key Points: 
  • With the participation of more than 350 specialist doctors from Latin American countries such as Panama, Guatemala, El Salvador, Nicaragua, Honduras, the Dominican Republic, Colombia, Bolivia, Chile, Paraguay, Peru, Mexico, Costa Rica, and Argentina, the second LatAm Ferrer Summit was held in Panama.
  • Over two days, the specialists had the opportunity to attend presentations on the latest scientific advances in these four therapeutic areas.
  • Under this Treedom project that Ferrer is partnering, so far more than 3 million trees have been planted in Africa, South America and Asia.
  • We empower and support these professionals in their learning and wellbeing so that they feel proud to work in our company.

DGAP-News: APONTIS PHARMA: SECURE study and START study add-on analysis confirm superior efficacy of Single Pill

Retrieved on: 
Thursday, September 1, 2022
Research, Clinical trial, Fortis Healthcare, Chronic kidney disease, Mount Sinai Medical Center, The New England Journal of Medicine, START, ASA, Heart failure, Degenerative disease, University of Kiel, Myocardial infarction, Physician, Union, Moyamoya disease, Atorvastatin, Centro Nacional de Aceleradores, Director general, APPH, CNIC, Stroke, Hypertension, Attention, ESC, European Congress of Radiology, Efficiency, Monheim am Rhein, Risk, Congress, Knowledge, MACE, Hyperlipidemia, Patient, Pharmaceutical industry, Medical device, Cardiology, Medicine, Ramipril, Cologne

The SECURE study and its results were published in the prestigious New England Journal of Medicine concurrent with its presentation at the Congress.

Key Points: 
  • The SECURE study and its results were published in the prestigious New England Journal of Medicine concurrent with its presentation at the Congress.
  • Prof. Dr. Burkhard Weisser (Kiel, Germany) presented the results of the add-on analysis to the START study conducted in Germany.
  • SECURE and START are the proof of principle of the Single Pill concept in a prospective study.
  • Since 2013, APONTIS PHARMA successfully launched several Single Pill products alone for cardiovascular indications such as hypertension, hyperlipidemia and secondary prevention.

The Polypill Reduces Cardiovascular Mortality by 33% in Patients Treated After Myocardial Infarction

Retrieved on: 
Friday, August 26, 2022
Research, Clinical Trials, Cardiology, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Mortality, Ramipril, European Society of Cardiology, Ferrer, Spanish National Center for Biotechnology, Death, The New England Journal of Medicine, Mount Sinai Hospital, Incidence, NEJM, Business development, Myocardial infarction, Union, ACE, Multimedia, Aspirin, Atorvastatin, FOCUS, CNIC, Hypertension, History, Population, Mount Sinai Hospital (Manhattan), ESC, Diabetes, Risk, Woman, Tobacco smoking, Czech Republic, Patient, Pharmaceutical industry, Medical device

The polypill reduces mortality from cardiovascular causes in this population by 33%.

Key Points: 
  • The polypill reduces mortality from cardiovascular causes in this population by 33%.
  • SECURE included 2499 patients from 7 European countries (Spain, Italy, Germany, the Czech Republic, France, Poland, and Hungary) recovering after a myocardial infarction.
  • The SECURE trial analyzed the incidence of four major cardiovascular events: death from cardiovascular causes, non-fatal myocardial infarction, non-fatal stroke, and emergency coronary revascularization (the restoration of blood flow through a blocked coronary artery).
  • The study followed patients for an average of 3 years and produced conclusive results: patients taking the polypill had a 24% lower risk of these four events than patients taking the three drugs separately.